Reyvow ® (lasmiditan) tablets CV

50 mg, 100 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

REYVOW® (lasmiditan): Half-Life

The elimination half-life of Reyvow (lasmiditan) is 5.7 hours.


Additional PK Characteristics

Lasmiditan was eliminated with a geometric mean t½ value of approximately 5.7 hours.1

No accumulation of lasmiditan was observed with daily dosing.1

Lasmiditan is primarily metabolized by ketone reduction to the alcohol S-M8, with very little parent drug (approximately 3%) excreted unchanged in urine.1

Renal excretion is a minor route of lasmiditan clearance.1


1Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.


PK = pharmacokinetics

t1/2 = elimination half-life

Date of Last Review: November 20, 2018

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical